Menu
Search
|

Menu

Close
X

Unum Therapeutics Inc UMRX.OQ (NASDAQ Stock Exchange Global Select Market)

12.00 USD
-- (--)
As of Apr 20
chart
Previous Close 12.00
Open --
Volume --
3m Avg Volume --
Today’s High --
Today’s Low --
52 Week High 12.25
52 Week Low 10.50
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
4
FY16
3
EPS (USD)
FY17
-0.464
FY16
-0.356
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
--
5.71
Price to Book (MRQ)
vs sector
--
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
--
16.45
LT Debt to Equity (MRQ)
vs sector
--
12.18
Return on Investment (TTM)
vs sector
--
14.38
Return on Equity (TTM)
vs sector
--
16.07

EXECUTIVE LEADERSHIP

Charles Wilson
Founder, President, Chief Executive Officer and Director, Since
Salary: --
Bonus: --
Dario Campana
Scientific Founder, Since
Salary: --
Bonus: --
Christiana Stamoulis
Chief Financial Officer, Head - Corporate Development, Since 2015
Salary: --
Bonus: --
Seth Ettenberg
Chief Scientific Officer, Since
Salary: --
Bonus: --
Ben Auspitz
Director, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Cambridgepark Dr Ste 3100
CAMBRIDGE   MA   02140-2307

Phone: +1617.9455576

Unum Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The Company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers, improving upon current cell therapies. The Company's product pipeline that includes clinical stage product candidates: ACTR087, ACTR087 (SEA-BCMA) and ACTR707.

SPONSORED STORIES